 NEW YORK, June 15, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN: ATNM Actinium today highlighted safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia rr AML were presented at the 2021 Society of Nuclear Medicine and Molecular Imaging SNMMI Annual Meeting held virtually July 11 th 14th. The presentation highlighted Iomab-Bs targeting ability and corresponding safety data from 113 patients, representing 75 of patient enrollment on the SIERRA trial. 